Understanding Hypertriglyceridemia: Integrating Genetic Insights
Genes · 30.01.2024 · 15 (2) · 190
DOI: 10.3390/genes15020190 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 30.01.2024. Verfasst von Mara Alves und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal. Hauptthemen laut MEDLINE: Pancreatitis, Hypertriglyceridemia. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hypertriglyceridemia is an exceptionally complex metabolic disorder characterized by elevated plasma triglycerides associated with an increased risk of acute pancreatitis and cardiovascular diseases such as coronary artery disease. Its phenotype expression is widely heterogeneous and heavily influenced by conditions as obesity, alcohol consumption, or metabolic syndromes. Looking into the genetic underpinnings of hypertriglyceridemia, this review focuses on the genetic variants in LPL, APOA5, APOC2, GPIHBP1 and LMF1 triglyceride-regulating genes reportedly associated with abnormal genetic transcription and the translation of proteins participating in triglyceride-rich lipoprotein metabolism. Hypertriglyceridemia resulting from such genetic abnormalities can be categorized as monogenic or polygenic. Monogenic hypertriglyceridemia, also known as familial chylomicronemia syndrome, is caused by homozygous or compound heterozygous pathogenic variants in the five canonical genes. Polygenic hypertriglyceridemia, also known as multifactorial chylomicronemia syndrome in extreme cases of hypertriglyceridemia, is caused by heterozygous pathogenic genetic variants with variable penetrance affecting the canonical genes, and a set of common non-pathogenic genetic variants (polymorphisms, using the former nomenclature) with well-established association with elevated triglyceride levels. We further address recent progress in triglyceride-lowering treatments. Understanding the genetic basis of hypertriglyceridemia opens new translational opportunities in the scope of genetic screening and the development of novel therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
- CGM-Centro de Genética Médica Jacinto de Magalhães, Centro Hospitalar Universitário de Santo António (CHUdSA), 4099-028 Porto, Portugal.
- UMIB-Unit for Multidisciplinary Research in Biomedicine, ICBAS-School of Medicine and Biomedical Sciences, University of Porto, 4050-346 Porto, Portugal.
- ITR-Laboratory for Integrative and Translational Research in Population Health, 4050-600 Porto, Portugal.
- UCIBIO Applied Molecular Biosciences Unit and Associate Laboratory i4HB-Institute for Health and Bioeconomy Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-3…
ORCID-Profile: Francisco Laranjeira, Georgina Correia-da-Silva
Zitieren
APA
Alves, M., Laranjeira, F., & Correia-da-Silva, G. (2024). Understanding Hypertriglyceridemia: Integrating Genetic Insights. Genes, 15(2), 190. https://doi.org/10.3390/genes15020190
Vancouver
Alves M, Laranjeira F, Correia-da-Silva G. Understanding Hypertriglyceridemia: Integrating Genetic Insights. Genes. 2024;15(2):190. doi:10.3390/genes15020190
BibTeX
@article{Alves2024,
author = {Alves, Mara and Laranjeira, Francisco and Correia-da-Silva, Georgina},
title = {Understanding Hypertriglyceridemia: Integrating Genetic Insights},
journal = {Genes},
year = {2024},
volume = {15},
number = {2},
pages = {190},
doi = {10.3390/genes15020190}
}
EUVIMED